Addex increases issued share capital to create treasury shares

Ad hoc announcement pursuant to art.   53 lr   geneva, switzerland, june 1 5 , 202 3 - addex therapeutics (six: adxn and nasdaq: adxn), a clinical-stage pharmaceutical company pioneering allosteric modulation-based drug discovery and development (“the company”), announced today that it has increased its share capital from chf 1,153,483.11 to chf 1,329,483.11 through the issue of 17,600,000 new registered shares at a nominal value of chf 0.01 each to addex pharma s.a, its 100% wholly-owned subsidiary.
ADXN Ratings Summary
ADXN Quant Ranking